Zhong Guo Zheng Quan Bao·2025-07-02 20:16Group 1 - The A-share market has seen a significant increase in private equity research activities, with 1,769 instances of private equity firms conducting research on 387 stocks across 28 industries in June [1] - The electronic, pharmaceutical, and machinery equipment sectors emerged as the primary focus areas for private equity research, with small-cap growth stocks attracting considerable attention [1][2] - Notable stocks such as Maiwei Biotech and Jingbeifang experienced intense research interest, with Maiwei Biotech receiving 51 research sessions, indicating a trend towards small-cap stocks with market capitalizations below 200 billion [1][2] Group 2 - The market performance of stocks that received private equity research correlates with the research intensity, as seen with Jingbeifang's stock price surging over 45% in June [2] - The pharmaceutical sector, particularly Maiwei Biotech, has garnered significant attention from top private equity firms, indicating a strong interest in this industry [2] - The electronic industry was the most researched sector, followed by pharmaceuticals and machinery equipment, with a total of 21 industries receiving focused research in June [2][3] Group 3 - There was little change in private equity research preferences from May to June, with a continued focus on electronics and pharmaceuticals [3] - A total of 85 private equity firms conducted five or more research sessions, with notable participation from large firms such as Zhengyuan Investment and Pankin Investment [3] - The outlook for the market suggests a focus on structural opportunities, with various private equity firms adopting different strategies [4] Group 4 - Some firms, like Shicheng Investment, express a cautious outlook on short-term index performance but remain optimistic about structural opportunities in sectors like Hong Kong internet giants and AI technology stocks [4] - Xing Shi Investment is optimistic about market sentiment recovery, citing improved economic fundamentals and favorable domestic policies [4] - Dan Yi Investment highlights a rotation between growth and dividend assets, suggesting a strategy focused on undervalued stocks with potential for future valuation increases [4] Group 5 - Huanrui Tianze's management is more bullish, suggesting the market may be in the early stages of a bull market, supported by favorable policies and liquidity [5] - The focus for Huanrui Tianze will be on the pharmaceutical sector, particularly innovative drugs, and consumer companies undergoing brand value reassessment [5]